Ovarian tumors endometrioid

Epithelial ovarian tumors are composed of cells that cover the surface of the ovary, such as serous, mucinous, endometrioid, clear cell, and poorly differentiated adenocarcinomas. 

While the risk that hormone replacement therapy may cause endometrial tumors has been widely discussed, less attention has been given to the possibility that it could increase the risk of epithelial ovarian cancer. Since cancer of the ovary has some risk factors in common with endometrial cancer (notably low parity and obesity), this possible risk needs to be considered, especially in view of the fact that the endometrioid epithelial type of ovarian tumor is histologically so similar to adenocarcinoma of the endometrium. 

Kabawat SE, Bast RC, Bhan AK, et al. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. Am Clin Pathol. 1983 79 98-104. 

Matias-Guiu X, Pons C, Prat J. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stro-mal tumors. Hum Pathol. 1998 29 840-845. 

In addition to the sex-cord stromal tumors, a variety of other benign and primary and metastatic malignant ovarian tumors may have a functioning stroma with estrogenic or androgenic production. However, these elevations will remain commonly subclinical. These tumors include mucinous tumors, rarely endometrioid carcinoma, malignant germ cell tumors, and mucinous metastatic carcinomas [37]. 

Patients with malignant tumors of the ovary and borderline tumors account for 21% and 4% of primary ovarian tumors, respectively [12], Among these, epithelial cancer constitutes for the vast majority with 85%. Serous epithelial and mucinous ovarian cancer account for the majority of epithelial ovarian cancers and present approximately 49% and 36% of all ovarian epithelial tumors, respectively [3], Endometrioid cell cancers account for 8%. The other cancers occur with equal frequency of 2% [3],... 

Nogales FF, Bergeron C, Carvia RE, et al. Ovarian endometrioid tumors with yolk sac tumor component, an unusual form of ovarian neoplasm—Analysis of six cases. Am J Surg Pathol. 1996 20 1056-1066. 

Ramalingam P, Malpica A, Silva EG, et al. The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas. Am J Surg Pathol. 2004 28 1499-1505. 

Vang R, Gown AM, Farinola M, et al. pl6 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary Utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol. 2007 31 653-663. 

Guerrieri C, Franlund B, Malmstrom H, et al. Ovarian endometrioid carcinomas simulating sex cord-stromal tumors A study using inhibin and cytokeratin 7. Int Gynecol Pathol. 1998 17 266-271. 

Roth LM, Liban E, Czernobilsky B. Ovarian endometrioid tumors mimicking Sertoli and Sertoli-Leydig cell tumors Sertoli-form variant of endometrioid carcinoma. Cancer. 1982 50 1322-1331. 

Aguirre P, Thor AD, Scully RE. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors. An immunohistochemical study. Int J Gynecol Pathol. 1989 8 364-373. 

Endometrioid carcinomas represent 8% of all ovarian carcinomas. They occur with synchronous endometrial carcinomas or endometrial hyperplasia in up to 33% of cases [39]. Furthermore, an association with breast cancer has been reported [2]. Rarely, endometrioid carcinoma may arise from endometriosis [40]. Bilateral ovarian involvement is encountered in 30%-50% of cases. Macroscopically, these tumors are solid and cystic, the cysts may contain mucinous or greenish fluid. Rarely, solid tumors with extensive hemorrhage or necrosis may be found [2]. 

---